At a glance
ClinicalIndex Comparison RecordPhase 2Active· 1,287 enrolled
Drug / intervention
Abelacimab +1 morebiological
Likely dose
Abelacimab 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, RandomiZed, Active-ControLled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab (MAA868) Compared With Open-Label Rivaroxaban in Patients With Atrial Fibrillation (AZALEA)
In Brief
A Phase 2 clinical trial evaluating Abelacimab and Rivaroxaban for Atrial Fibrillation (AF) and Stroke. Active but no longer recruiting, targeting 1,287 participants across 92 sites in 7 countries.
Detailed Summary
The purpose of the ANT-006 study is to evaluate the bleeding profile of abelacimab relative to rivaroxaban in patients with atrial fibrillation (AF) at moderate-to-high risk of stroke.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation (AF), Stroke
CountriesCanada, Czechia, Hungary, Poland, South Korea, Taiwan, United States
CollaboratorsNovartis Pharmaceuticals
Timeline
Phase 2Active
202120222023202420252026202720282029
Enrollment StartFeb 2021
First PostedFeb 2021
Primary CompletionFeb 2024
TodayJul 2026
Study CompletionDec 2028
First PostedFeb 16, 2021
Enrollment StartFeb 2, 2021
Primary CompletionFeb 15, 2024
Study CompletionDec 29, 2028
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 5.4 years ago
Interventions
Abelacimabbiological
Abelacimab provided as liquid in vial (150 mg/mL)
Rivaroxabandrug
Rivaroxaban 15 mg and 20 mg provided as commercially available film-coated tablets